BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

08-06-2018

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

vladimirsorokin / iStockphoto.com

Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration (FDA).


pharmaceutical, US Food and Drug Administration, Scott Gottlieb, BIO, BIO 2018, generics, generic, FDA

LSIPR